Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
DRUG: Zumsemetinib|DRUG: Capecitabine|DRUG: Zoledronic acid|DRUG: Denosumab
Number of participants with adverse events (Phase Ib only), From start of treatment through 30 days after end of treatment (estimated to be 11 months)|Recommended phase II dose of zunsemetinib (Phase Ib only), Through end of 1st cycle (each cycle is 21 days)|Number of participants with dose-limiting toxicities (Phase Ib only), Through end of 1st cycle (each cycle is 21 days)|Percent change in serum CTX (Phase II only), Baseline and Day 1 of week 7|Progression-free survival (PFS) (Phase II only), From start of treatment through completion of follow-up (estimated to be 3 years and 10 months)
Treatment-induced changes in DEXA BMD (g/cm^2) at hip and spine (Phase Ib only), Baseline, end of cycle 8 (each cycle is 21 days), and end of treatment (estimated to be 10 months)|Treatment-induced changes in sCTX by clinical assay (Phase II only), Baseline, cycle 1 day 1 pre-dose, cycle 1 day 8 pre-dose, cycle 1 day 15 pre-dose, day 1 of subsequent cycles (each cycle is 21 days), and end of treatment (estimated to be 10 months)|Objective response rate (ORR) (Phase II only), Through completion of treatment (estimated to be 10 months)|Clinical benefit rate (Phase II only), Through completion of treatment (estimated to be 10 months)|Overall survival (OS) (Phase II only), From start of treatment through completion of follow-up (estimated to be 3 years and 10 months)|Treatment-induced changes in DEXA BMD (g/cm^2) at hip and spine (Phase II only), Baseline, end of cycle 8, and end of treatment (estimated to be 10 months)|Treatment-induced changes in quality of life as measured by EORTC QLQ-C30 (Phase II only), Prior to start of 1st treatment, cycle 5 day 1, every 4 cycles thereafter (each cycle is 21 days), and at the time of progression (estimated to be 3 years and 10 months)|Treatment-induced changes in pain as measured by Brief Pain Inventory (BPI) (Phase II only), Prior to start of 1st treatment, cycle 5 day 1, every 4 cycles thereafter (each cycle is 21 days), and at the time of progression (estimated to be 3 years and 10 months)|Number of participants with adverse events (Phase II only), From start of treatment through 30 days after end of treatment (estimated to be 11 months)
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).